argenex (ARGX) Competitors $591.99 +0.25 (+0.04%) Closing price 04:00 PM EasternExtended Trading$591.96 -0.03 (-0.01%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARGX vs. SNY, GSK, TAK, ONC, BNTX, INSM, SMMT, TEVA, ITCI, and GMABShould you be buying argenex stock or one of its competitors? The main competitors of argenex include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry. argenex vs. Its Competitors Sanofi GSK Takeda Pharmaceutical BeOne Medicines BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S argenex (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Is ARGX or SNY more profitable? argenex has a net margin of 40.20% compared to Sanofi's net margin of 14.56%. Sanofi's return on equity of 17.15% beat argenex's return on equity.Company Net Margins Return on Equity Return on Assets argenex40.20% 16.15% 14.33% Sanofi 14.56%17.15%9.80% Which has stronger earnings and valuation, ARGX or SNY? Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioargenex$2.25B16.09$833.04M$16.2136.52Sanofi$44.46B2.78$6.02B$2.8017.99 Do institutionals & insiders believe in ARGX or SNY? 60.3% of argenex shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, ARGX or SNY? argenex has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Does the media prefer ARGX or SNY? In the previous week, Sanofi had 1 more articles in the media than argenex. MarketBeat recorded 22 mentions for Sanofi and 21 mentions for argenex. Sanofi's average media sentiment score of 0.98 beat argenex's score of 0.38 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 12 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ARGX or SNY? argenex presently has a consensus price target of $728.06, indicating a potential upside of 22.99%. Sanofi has a consensus price target of $61.50, indicating a potential upside of 22.10%. Given argenex's higher possible upside, equities research analysts clearly believe argenex is more favorable than Sanofi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenex 0 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 2 Strong Buy rating(s) 3.10Sanofi 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.11 Summaryargenex beats Sanofi on 9 of the 17 factors compared between the two stocks. Get argenex News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.21B$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio36.528.6721.1920.14Price / Sales16.09328.69461.30104.37Price / Cash199.2142.7636.2258.56Price / Book6.548.378.665.87Net Income$833.04M-$55.19M$3.25B$258.55M7 Day Performance4.85%5.89%4.20%2.23%1 Month Performance5.61%17.63%10.82%12.76%1 Year Performance21.73%5.09%34.70%19.36% argenex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenex3.6805 of 5 stars$591.99+0.0%$728.06+23.0%+27.4%$36.21B$2.25B36.521,599Trending NewsUpcoming EarningsAnalyst RevisionSNYSanofi3.5174 of 5 stars$48.55-0.1%$61.50+26.7%-2.1%$119.07B$44.46B17.3482,878Upcoming EarningsGSKGSK1.7307 of 5 stars$38.34+0.1%$37.38-2.5%-2.8%$78.49B$40.10B19.7668,629Trending NewsUpcoming EarningsAnalyst RevisionTAKTakeda Pharmaceutical1.6897 of 5 stars$15.04+2.4%N/A+8.0%$47.84B$30.09B68.3447,455Upcoming EarningsHigh Trading VolumeONCBeOne Medicines1.2886 of 5 stars$252.14+0.7%$320.67+27.2%N/A$27.63B$3.81B-67.7811,000Insider TradeGap DownBNTXBioNTech1.409 of 5 stars$111.00-1.7%$137.91+24.2%+37.8%$26.68B$2.98B-32.656,772News CoverageINSMInsmed3.9532 of 5 stars$101.89+3.8%$108.07+6.1%+39.1%$19.33B$381.03M-17.121,271Positive NewsAnalyst ForecastInsider TradeSMMTSummit Therapeutics2.1516 of 5 stars$25.40+1.6%$34.67+36.5%+176.3%$18.86BN/A-74.70110Positive NewsTEVATeva Pharmaceutical Industries4.4316 of 5 stars$16.43+0.2%$24.71+50.5%-0.8%$18.84B$16.54B-14.2836,830Upcoming EarningsITCIIntra-Cellular Therapies0.8898 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0706 of 5 stars$21.46+0.3%$37.80+76.1%-15.2%$13.77B$3.12B12.192,682Positive News Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ONC Alternatives BNTX Alternatives INSM Alternatives SMMT Alternatives TEVA Alternatives ITCI Alternatives GMAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARGX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenex SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
